Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis.

WWARN Parasite Clearance Study Group, Abdulla S, Ashley EA, Bassat Q, Bethell D, Björkman A, Borrmann S, D'Alessandro U, Dahal P, Day NP, Diakite M, Djimde AA, Dondorp AM, Duong S, Edstein MD, Fairhurst RM, Faiz MA, Falade C, Flegg JA, Fogg C, Gonzalez R, Greenwood B, Guérin PJ, Guthmann JP, Hamed K, Hien TT, Htut Y, Juma E, Lim P, Mårtensson A, Mayxay M, Mokuolu OA, Moreira C, Newton P, Noedl H, Nosten F, Ogutu BR, Onyamboko MA, Owusu-Agyei S, Phyo AP, Premji Z, Price RN, Pukrittayakamee S, Ramharter M, Sagara I, Se Y, Suon S, Stepniewska K, Ward SA, White NJ, Winstanley PA.

Malar J. 2015 Sep 22;14:359. doi: 10.1186/s12936-015-0874-1.

2.

Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria.

Bell DJ, Nyirongo SK, Mukaka M, Molyneux ME, Winstanley PA, Ward SA.

Clin Pharmacol Ther. 2011 Feb;89(2):268-75. doi: 10.1038/clpt.2010.297. Epub 2010 Dec 29.

PMID:
21191379
3.

Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria.

Tiono AB, Dicko A, Ndububa DA, Agbenyega T, Pitmang S, Awobusuyi J, Pamba A, Duparc S, Goh LE, Harrell E, Carter N, Ward SA, Greenwood B, Winstanley PA.

Am J Trop Med Hyg. 2009 Dec;81(6):969-78. doi: 10.4269/ajtmh.2009.09-0351.

4.

Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi.

Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, Hughes DA, Molyneux ME, Ward SA, Winstanley PA, Lalloo DG.

Malar J. 2009 Aug 26;8:204. doi: 10.1186/1475-2875-8-204.

5.

Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria.

Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, Oguche S, Borrmann S, Sowunmi A, Duparc S, Kirby PL, Pamba A, Kellam L, Guiguemdé R, Greenwood B, Ward SA, Winstanley PA.

PLoS One. 2009 Aug 19;4(8):e6682. doi: 10.1371/journal.pone.0006682.

6.

Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.

Miller AK, Bandyopadhyay N, Wootton DG, Duparc S, Kirby PL, Winstanley PA, Ward SA.

Eur J Clin Pharmacol. 2009 Oct;65(10):977-87. doi: 10.1007/s00228-009-0672-1. Epub 2009 Jun 11.

PMID:
19517101
7.

Plasmodium falciparum and dihydrofolate reductase I164L mutations in Africa.

Alker AP, Juliano JJ, Meshnick SR, Owen A, Ochong E, Bell DJ, Johnson DJ, d'Alessandro U, Mulenga M, Muangnoicharoen S, Van Geertruyden JP, Winstanley PA, Bray PG, Ward SA.

Antimicrob Agents Chemother. 2009 Apr;53(4):1722; author reply 1722-3. doi: 10.1128/AAC.01427-08. No abstract available.

8.

Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.

O'Neill PM, Shone AE, Stanford D, Nixon G, Asadollahy E, Park BK, Maggs JL, Roberts P, Stocks PA, Biagini G, Bray PG, Davies J, Berry N, Hall C, Rimmer K, Winstanley PA, Hindley S, Bambal RB, Davis CB, Bates M, Gresham SL, Brigandi RA, Gomez-de-Las-Heras FM, Gargallo DV, Parapini S, Vivas L, Lander H, Taramelli D, Ward SA.

J Med Chem. 2009 Apr 9;52(7):1828-44. doi: 10.1021/jm8012757.

9.

Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.

O'Neill PM, Park BK, Shone AE, Maggs JL, Roberts P, Stocks PA, Biagini GA, Bray PG, Gibbons P, Berry N, Winstanley PA, Mukhtar A, Bonar-Law R, Hindley S, Bambal RB, Davis CB, Bates M, Hart TK, Gresham SL, Lawrence RM, Brigandi RA, Gomez-delas-Heras FM, Gargallo DV, Ward SA.

J Med Chem. 2009 Mar 12;52(5):1408-15. doi: 10.1021/jm8012618.

PMID:
19222165
10.

Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure.

Ochong E, Bell DJ, Johnson DJ, D'Alessandro U, Mulenga M, Muangnoicharoen S, Van Geertruyden JP, Winstanley PA, Bray PG, Ward SA, Owen A.

Antimicrob Agents Chemother. 2008 Nov;52(11):3883-8. doi: 10.1128/AAC.00431-08. Epub 2008 Aug 25.

11.

Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria.

Wootton DG, Opara H, Biagini GA, Kanjala MK, Duparc S, Kirby PL, Woessner M, Neate C, Nyirenda M, Blencowe H, Dube-Mbeye Q, Kanyok T, Ward S, Molyneux M, Dunyo S, Winstanley PA.

PLoS One. 2008 Mar 5;3(3):e1779. doi: 10.1371/journal.pone.0001779.

12.

Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi.

Bell DJ, Nyirongo SK, Mukaka M, Zijlstra EE, Plowe CV, Molyneux ME, Ward SA, Winstanley PA.

PLoS One. 2008 Feb 13;3(2):e1578. doi: 10.1371/journal.pone.0001578.

13.

Reconciling national treatment policies and drug regulation in Kenya.

Amin AA, Walley T, Kokwaro GO, Winstanley PA, Snow RW.

Health Policy Plan. 2007 Mar;22(2):111-2. Epub 2007 Jan 15. No abstract available.

14.

Practical HPLC methods for the quantitative determination of common antimalarials in Africa.

Bell DJ, Nyirongo SK, Molyneux ME, Winstanley PA, Ward SA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 1;847(2):231-6. Epub 2006 Nov 13.

PMID:
17098484
15.

Therapeutic potential of folate uptake inhibition in Plasmodium falciparum.

Nzila AM, Kokwaro G, Winstanley PA, Marsh K, Ward SA.

Trends Parasitol. 2004 Mar;20(3):109-12. Review.

PMID:
16676416
16.

Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites.

Bates SJ, Winstanley PA, Watkins WM, Alloueche A, Bwika J, Happi TC, Kremsner PG, Kublin JG, Premji Z, Sibley CH.

J Infect Dis. 2004 Nov 15;190(10):1783-92. Epub 2004 Oct 18.

PMID:
15499534
17.

The difference between effectiveness and efficacy of antimalarial drugs in Kenya.

Amin AA, Hughes DA, Marsh V, Abuya TO, Kokwaro GO, Winstanley PA, Ochola SA, Snow RW.

Trop Med Int Health. 2004 Sep;9(9):967-74.

18.

The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses.

Watkins WM, Mberu EK, Winstanley PA, Plowe CV.

Parasitol Today. 1997 Dec;13(12):459-64.

PMID:
15275132
19.

Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial.

Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, Fehintola FA, Horton J, Jaffar S, Kanyok T, Kremsner PG, Kublin JG, Lang T, Missinou MA, Mkandala C, Oduola AM, Premji Z, Robertson L, Sowunmi A, Ward SA, Winstanley PA.

Lancet. 2004 Jun 5;363(9424):1843-8.

PMID:
15183620
20.

Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials.

O'Neill PM, Mukhtar A, Stocks PA, Randle LE, Hindley S, Ward SA, Storr RC, Bickley JF, O'Neil IA, Maggs JL, Hughes RH, Winstanley PA, Bray PG, Park BK.

J Med Chem. 2003 Nov 6;46(23):4933-45.

PMID:
14584944
21.

The effect of quinine on the electroretinograms of children with pediatric cerebral malaria.

Lochhead J, Movaffaghy A, Falsini B, Winstanley PA, Mberu EK, Riva CE, Molyneux ME, Taylor TE, Harding SP.

J Infect Dis. 2003 Apr 15;187(8):1342-5. Epub 2003 Apr 2.

PMID:
12696018
22.

Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial.

Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, Molyneux ME, Marsh K, Taylor TE, Watkins WM, Winstanley PA.

Lancet. 2002 Oct 12;360(9340):1136-43.

PMID:
12387962
23.

Clinical status and implications of antimalarial drug resistance.

Winstanley PA, Ward SA, Snow RW.

Microbes Infect. 2002 Feb;4(2):157-64.

PMID:
11880047
24.

Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.

Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV.

J Infect Dis. 2002 Feb 1;185(3):380-8. Epub 2002 Jan 17.

PMID:
11807721
25.

Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?

Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM.

Trends Parasitol. 2001 Dec;17(12):582-8. Review.

PMID:
11756042
26.

New agents to combat malaria.

Beeson JG, Winstanley PA, McFadden GI, Brown GV.

Nat Med. 2001 Feb;7(2):149-50. No abstract available.

PMID:
11175835
27.

Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum.

Nzila AM, Nduati E, Mberu EK, Hopkins Sibley C, Monks SA, Winstanley PA, Watkins WM.

J Infect Dis. 2000 Jun;181(6):2023-8. Epub 2000 Jun 5. Erratum in: J Infect Dis 2000 Sep;182(3):1011.

PMID:
10837185
28.

Disposition of intravenous pyrimethamine in healthy volunteers.

Almond DS, Szwandt IS, Edwards G, Lee MG, Winstanley PA.

Antimicrob Agents Chemother. 2000 Jun;44(6):1691-3.

29.

Chemotherapy for falciparum malaria: the armoury, the problems and the prospects.

Winstanley PA.

Parasitol Today. 2000 Apr;16(4):146-53. Review.

PMID:
10725901
30.
31.

Biliary metabolites of beta-artemether in rats: biotransformations of an antimalarial endoperoxide.

Maggs JL, Bishop LP, Edwards G, O'Neill PM, Ward SA, Winstanley PA, Park BK.

Drug Metab Dispos. 2000 Feb;28(2):209-17.

PMID:
10640520
32.
33.

More on 'the efficacy of antifolate antimalarial combinations in Africa'.

Watkins WM, Mberu EK, Winstanley PA, Plowe CV.

Parasitol Today. 1999 Apr;15(4):131-2. No abstract available.

PMID:
10322331
34.

Quinine sensitivity of isolates of Plasmodium falciparum from the coast of Kenya.

Haruki K, Winstanley PA, Watkins WM, Marsh K.

Trans R Soc Trop Med Hyg. 1998 Mar-Apr;92(2):195-6. No abstract available.

PMID:
9764332
35.

Clinical pharmacology and malaria.

Breckenridge AM, Winstanley PA.

Ann Trop Med Parasitol. 1997 Oct;91(7):727-33. Review.

PMID:
9625927
36.
37.

Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.

Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK.

J Infect Dis. 1997 Dec;176(6):1590-6.

PMID:
9395372
38.

Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria.

Amukoye E, Winstanley PA, Watkins WM, Snow RW, Hatcher J, Mosobo M, Ngumbao E, Lowe B, Ton M, Minyiri G, Marsh K.

Antimicrob Agents Chemother. 1997 Oct;41(10):2261-4.

39.

Photographic and angiographic characterization of the retina of Kenyan children with severe malaria.

Hero M, Harding SP, Riva CE, Winstanley PA, Peshu N, Marsh K.

Arch Ophthalmol. 1997 Aug;115(8):997-1003.

PMID:
9258221
40.
41.

Coma scales for children with severe falciparum malaria.

Newton CR, Chokwe T, Schellenberg JA, Winstanley PA, Forster D, Peshu N, Kirkham FJ, Marsh K.

Trans R Soc Trop Med Hyg. 1997 Mar-Apr;91(2):161-5.

PMID:
9196757
42.

Intracranial hypertension in Africans with cerebral malaria.

Newton CR, Crawley J, Sowumni A, Waruiru C, Mwangi I, English M, Murphy S, Winstanley PA, Marsh K, Kirkham FJ.

Arch Dis Child. 1997 Mar;76(3):219-26.

43.

Severe anaemia in children living in a malaria endemic area of Kenya.

Newton CR, Warn PA, Winstanley PA, Peshu N, Snow RW, Pasvol G, Marsh K.

Trop Med Int Health. 1997 Feb;2(2):165-78.

44.

Fatal quinine cardiotoxicity in the treatment of falciparum malaria.

Bonington A, Davidson RN, Winstanley PA, Pasvol G.

Trans R Soc Trop Med Hyg. 1996 May-Jun;90(3):305-7. No abstract available.

PMID:
8758086
45.

Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma.

Watkins WM, Mungai M, Muhia DK, Mberu EK, Gathua S, Winstanley PA, Gilks CF, Nunn P.

Br J Clin Pharmacol. 1996 Feb;41(2):160-2.

46.

Generation effects and the lack thereof: the role of transfer-appropriate processing.

de Winstanley PA, Bjork EL, Bjork RA.

Memory. 1996 Jan;4(1):31-48.

PMID:
8821084
47.

Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine.

Murphy S, Watkins WM, Bray PG, Lowe B, Winstanley PA, Peshu N, Marsh K.

Am J Trop Med Hyg. 1995 Sep;53(3):303-5.

PMID:
7573718
48.

The management of severe malaria in children: a review.

Murphy S, English M, Omar A, Crawley J, Waruiru C, Mwangi I, Amukoye E, Peshu N, Newton CR, Winstanley PA, et al.

East Afr Med J. 1995 Aug;72(8):536-9. Review.

PMID:
7588152
49.

In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs.

Winstanley PA, Mberu EK, Szwandt IS, Breckenridge AM, Watkins WM.

Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.

50.

Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria.

Watkins WM, Winstanley PA, Mberu EK, Kokwaro G, Murphy SA, Newton CJ, Mwangi I, Forster D, Marsh K.

Br J Clin Pharmacol. 1995 Mar;39(3):283-7.

Supplemental Content

Loading ...
Support Center